Remicade biosimilar launched in USA with 35% discount on original

24 July 2017

South Korean biosimilar drugs developer Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), has announced the launch of its first biosimilar in the USA.

Following approval from the US Food and Drug Administration (FDA) in April of this year, Renflexis, a biosimilar referencing the immunotherapy Remicade (infliximab), has been made available in the USA, where it is being commercialized by US pharma giant Merck & Co (NYSE: MRK).

"We will continue our relentless drive to advance one of the industry’s strongest pipelines"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK